Neurological disorders Archives

tourette syndrome treatment noema pharma

News and Trends 7 Dec 2020

Swiss Startup Tackles Tourette’s Syndrome Despite Recent Failures

In spite of recent failures of clinical trials from others in the field, Swiss company Noema Pharma is gearing up to develop better treatments for the neurological condition Tourette’s syndrome. Noema Pharma will use a recent €49M Series A round to bankroll the phase I development of a candidate for Tourette’s syndrome along with the […]

December 7, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 7 Oct 2020

Investment Is Pouring Into Neuromodulation Treatments

The last month has seen several big investments in European neuromodulation and neurostimulation companies, which aim to treat neurological conditions by zapping nerve cells. What’s the reason for this funding peak? Last week, the Italian firm WISE announced the closing of a €15M Series C round to fund the development of a device that blocks […]

October 7, 2020 - 6 minutesmins - By Helen Albert

Interview 2 Sep 2020

An Alzheimer’s Vaccine Challenged the Consensus for 25 Years

For decades, Alzheimer’s disease research focused on a hypothesis that has increasingly been contested. A team of scientists in Slovakia has been swimming against the tide since the beginning, going for an alternative approach that has only recently started gaining recognition. Research in Alzheimer’s disease has recently been plagued by intense disappointment. For over 25 […]

September 2, 2020 - 8 minutesmins - By Farhan Mitha

News and Trends 18 Aug 2020

Women’s Health Gains Traction as Bayer Pays €736M for UK Firm

Bayer’s recent €736M ($875M) acquisition of KaNDy Therapeutics could herald growing investor interest in women’s health – a historically neglected field in the biotech and pharma industry. Through this deal, Bayer has snapped up KaNDy Therapeutics’ first-in-class drug for treating hot flashes and night sweats, which often occur during the menopause. In a phase IIb […]

August 18, 2020 - 3 minutesmins - By Jonathan Smith

sonoran desert toad psychedelic beckley psytech

News and Trends 1 Jul 2020

UK Startup Bags €3M to Develop Psychedelic Medicines for Mental Health

A €3.3M (£3M) Series A round raised by the Oxford-based biomedicine company Beckley Psytech will allow the company to study the use of a psychedelic compound for the treatment of mental health disorders and neuropsychiatric disease. The investors include the UK VC firms Mediqventures and Jamjar Investments, which was set up by Richard Reed, co-founder […]

July 1, 2020 - 3 minutesmins - By Kostas Vavitsas

News and Trends 11 Jun 2020

Evox and Lilly Partner to Develop Neuro RNA Drugs in Deal Worth €1.1B

British biotech Evox Therapeutics has signed a collaboration deal worth up to €1.1B with US big pharma Eli Lilly to develop RNA drugs that are delivered in exosomes to the brain to treat neurological diseases. As part of the deal, Evox will get €17.6M upfront to fund research for the next three years and Lilly […]

June 11, 2020 - 3 minutesmins - By Helen Albert

huntingtons disease dementia prilenia therapeutics

News and Trends 5 Jun 2020

Israeli-Dutch Biotech Raises €55M to Fight Huntington’s Disease and ALS

Prilenia Therapeutics has raised €55M in Series A funding to launch late-stage clinical trials of its small molecule candidate drug in Huntington’s disease and amyotrophic lateral sclerosis, incurable conditions that have very limited treatment options. Dutch life sciences VC Forbion led the round and was joined by new Chinese investor Morningside Venture Investments and the […]

June 5, 2020 - 3 minutesmins - By Helen Albert

central nervous system epilepsy parkinsons disease

News and Trends 29 May 2020

Spanish Neurology Biotech Launches with €7.6M Series A

Accure Therapeutics, a neurology biotech targeting central nervous system (CNS) conditions such as multiple sclerosis and Parkinson’s disease, has launched in Barcelona with a Series A of €7.6M. Alta Life Sciences, a life science venture capital firm based in the same city, and the Spanish governmental institution The Centre for Technological and Industrial Development funded […]

May 29, 2020 - 3 minutesmins - By Helen Albert

News and Trends 8 May 2020

Phase III Failure Sinks Drug for Rare Neurological Disorder

The Italian biotech Newron is halting the development of the experimental drug sarizotan after it failed to meet efficacy endpoints in phase III, dashing hopes for an approved drug for Rett syndrome. Expectations had been high that the oral drug might be able to treat breathing difficulties associated with the rare genetic disorder after promising […]

May 8, 2020 - 4 minutesmins - By Anita Chakraverty

brainvectis askbio gene therapy neurology

News and Trends 28 Apr 2020

AskBio Takes Over French Gene Therapy Company to Treat Alzheimer’s and Huntington’s

The Paris-based BrainVectis, a biotech developing gene therapies for Huntington’s disease and Alzheimer’s disease, has been acquired by the US clinical-stage gene therapy company AskBio. AskBio’s gene therapy experience and manufacturing capacity will help to accelerate BrainVectis’ lead candidate for Huntington’s into phase I testing. In return, AskBio gets to expand its list of target […]

April 28, 2020 - 3 minutesmins - By David Kirk

News and Trends 21 Apr 2020

Idorsia’s Drug Improves Sleep in First Phase III Trial for Insomnia

The Swiss pharmaceutical company Idorsia has announced that its drug candidate daridorexant significantly improved sleep onset, sleep quality, and daytime functioning of insomnia patients in a pivotal phase III trial. The trial recruited 930 adult patients with insomnia. The company used a technique called polysomnography to measure the time taken to fall asleep and sleep […]

April 21, 2020 - 3 minutesmins - By Karen O’Hanlon Cohrt

epigenetics review cambridge epigenetix oryzon1

News and Trends 9 Apr 2020

Two European Alzheimer’s Disease Treatments Show Promise in Phase II

An epigenetics drug developed by the Spanish biopharmaceutical company Oryzon has reduced aggressive behavior in patients with Alzheimer’s disease and improved the experience of their caregivers in a phase IIa trial. At the same time, an Alzheimer’s vaccine developed by the Austrian biotech Axon Neuroscience has lowered a key blood biomarker of neurodegeneration by almost […]

April 9, 2020 - 4 minutesmins - By David Kirk

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us